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(heterozygous flaw of the VHL gene), up to 60-80% of them will develop HBs in their lifetime. [6] [7] [8] [9] However, most previous correlative genetic analysis considered only heterozygote (not homozygote) of the VHL gene. Furthermore, HB occurs by two accumulating mutation in a recessive single VHL gene, either an inherited mutation copy in one allele followed by a randomly acquired mutation in another allele (familiar HB), or two sequential randomly induced mutation-one in each allele of the VHL gene (sporadic HB). The "first hit" (first mutation)
has been investigated in great detail; however, little is known about the nature of the second hit. 10 In fact, this process, despite catering to the fact that sporadic HBs on average occur later than familial HBs, is speculative and remains unclear. It seems that the large discrepancy of the mutation rate in the two alleles within the same cell cannot be simply explained by random mutation. For example, the predicted mutation rate of two times (alleles) is 1:4.4 × 10 −6 versus 1:0.6-0.8, respectively, in familial HBs (the ratio of two allele mutation rate is 1:2.64 ∼ 3.52 × 10 6 ), [11] [12] [13] with a similar rate in sporadic HBs. 14 It is possible that a random mutation in one allele of the VHL gene could contribute to the next mutation in another allele. In this regard, it is important to take into account the heterozygosity of the VHL gene in the VHL-defect carriers. 4 Moreover, a homozygous VHL defect animal by acute genetic engineering in fact overlooks the predisposition process caused by the heterozygous VHL deficiency, implying that a background of the underlying molecular conditions has been changed, 5′-CTCCCCTTCAGCTGGACAC-3′; s248: 5′-CCACTACCTGCT-CAGGCGTGAG-3′; s211: 5′-GGACTTCTTCTCCTCCAGCTCG-3′.
| Middle cerebral artery occlusion and reperfusion (MCAO/R) model
Wild-type C57/BL6 and VHL heterozygous (+/−) mice were kept in standard housing conditions. MCAO model was established in mice as described previously, with minor modifications. 22 Briefly, after fasting for 12 h, anesthesia was performed in all animals using intraperitone- 
| Behavioral testing
Modified neurological severity score (mNSS) was examined in wide type and VHL heterozygous (+/−) knockout mice (each n = 12) before and at 1, 3, 5, 7 days after MCAO in a blinded manner. mNSS is a comprehensive test for evaluating motor, sensory, reflex, and balance abilities. Neurological deficits were graded on a scale of 0-18, and score points were awarded when mice were unable to perform the tests or lacked tested reflexes. Therefore, a higher score represents a more severe injury. 23 Limb placing score was initially used for assessing lateralized sensorimotor dysfunction of experimental stroke mice, and has also been translated to the mouse MCAO model recently. 20 Briefly, mice were brought laterally toward the benchtops, allowing for spontaneous placement of the forelimbs. Mice were then gently pulled down, forcing the limbs away from the bench top edge. Forelimb retrieval and placement were observed and graded as follows: 0 = immediate and complete placement; 1 = delayed or incomplete placement (>2 s); and 2 = no placement.
Elevated body swing test was used to evaluate asymmetrical motor behavior. 24 Mice were held by tails, and the direction of the body swing, defined as an upper body turn of >10°to either side, was recorded for 30 trials each time. The numbers of left and right turns were counted, and final results were presented as the percentages of turns to the ischemia-impaired side (left side) out of 30 total trials.
| Quantification of infarct volume
At 7 days after MCAO, mice were decapitated and their brains were rapidly removed and frozen, and cut into 2-mm-thick coronal sections.
Infarct volume was measured according to the procedure described previously. 25 Slices were stained with 1. 
| Immunohistochemical (IHC) assay
On day 7 after MCAO, the anesthetized mice were sacrificed by decapitation (n = 8 for each group). The brains were rapidly removed and placed in 4% paraformaldehyde at 4°C for 48 h. Samples were incubated at 4°C overnight with primary antibodies against Caspase-3 (Santa Cruz Biotechnology) and glial fibrillary acidic protein (GFAP; Cell Signaling Technology Inc., Beverly, MA) at the concentrations of 1:100.
As secondary antibody, immunoglobulin G conjugated with horseradish peroxidase (HRP) (Promega Biotechnology Co., Ltd., Beijing, China) was used at 37°C for 30 min. Before dehydration and mounting, slides were counterstained with hematoxylin. The marker-specific cells throughout the entire section (three sections per antibody staining)
were counted and then the total counts in these sections were converted into cell densities for quantification.
| Statistical analysis
Quantitative data were presented as mean ± standard deviation (SD).
Unpaired student t-test (two tailed) was applied to analyze the difference between two groups, and one-way ANOVA was applied to analyze the difference between more than two groups. All statistical analyses were performed using commercially available software (SPSS version 19.0, SPSS, Inc., Chicago, IL). P < 0.05 was considered as statistically significant.
3 | RESULTS
| Generation of VHL knockout mice
TALEN constructs were created that targeted the DNA sequence of the mouse VHL gene (Fig. 1A) . The TALEN binding sites were located on VHL Exon 1 (Fig. 1B) . TALEN mRNAs were transcribed in vitro and then injected into the cytoplasm of one-cell mouse embryos. Following transfer of injected embryos to pseudopregnant recipients, 18 liveborn offspring were produced (F0). Offspring were screened for targeted disruption of VHL Exon 1 by PCR amplification and DNA sequence analysis. Of the 18 live-born mice produced at the first batch of mice, there were five founder mice that showed mutations in the VHL gene, including GG deletion, GCC deletion, CG insertion, GCGGCC deletion, and GCC deletion (Fig. 1C) . 
| VHL deletion decreased the severity of cerebral ischemia in MCAO mice
To evaluate whether VHL heterozygous knockout affects functional recovery from MCAO, mNSS, limb placing score and elevated body swing test were used to estimate neurological deficit at different time points following MCAO. mNSS score was significantly decreased in the VHL heterozygous (+/−) knockout mice, compared with the wild-type mice 3, 5, and 7 days after MCAO (P < 0.01, Fig. 2A ). Limb placing score was significantly decreased in the VHL heterozygous (+/−) knockout mice, compared with wild type mice 5 and 7 days after MCAO (P < 0.05, Fig. 2B ). Elevated body swing test score was significantly decreased in the VHL heterozygous (+/−) knockout mice, compared with wild-type mice 5 and 7 days after MCAO (P < 0.05, Fig. 2C ).
To investigate whether VHL heterozygous knockout affects acute infarct damage from MCAO, we compared infarct volume between wide type and VHL heterozygous knockout mice. At day 7 after
MCAO, a series of sections showed extensive infarction by TTC staining in the cerebral cortical and subcortical areas (Fig. 2D ). In MCAO model, infarct volume accounted for more than half of the whole hemisphere. VHL heterozygous mice had significantly smaller infarct volume than wide type mice (P < 0.01, Fig. 2E ).
| VHL deletion increased the expression of HIF-1α and its downstream genes, and Twist 1 in the ischemic brain
To test whether VHL deletion could affect the cerebral HIF-1α gene expression, qRT-PCR assay and Western blot analysis were performed to measure HIF-1α mRNA and protein expressions in ischemic boundary zone. We found that the MCAO model group had significantly increased HIF-1α mRNA and protein levels, compared with the sham group (P < 0.01, Fig. 3A,D,E) . Moreover, VHL deletion significantly increased HIF-1α mRNA and protein levels in the ischemic boundary zone 7 days after MCAO (P < 0.01). We further measured mRNA expressions of EPO and VEGF, two downstream genes of HIF-1α. Compared to wild-type mice, VHL heterozygous mice showed significantly increased EPO and VEGF mRNA levels 7 days after MCAO (P < 0.01, Fig. 3B,C) . Meanwhile, we also detected Twist 1 expression, a HIF-independent angiogenic gene. qRT-PCR assay and Western blot analysis showed that the expressions of Twist 1 mRNA and protein in ischemic boundary zone increased significantly in VHL heterozygous mice group, compared with the wild-mice group after MCAO (P < 0.01, Fig. 3D ,F,G).
| VHL deletion showed neuroprotective effects in MCAO mice
In order to explore the neuroprotective effects of VHL deletion, immunohistochemical assay was performed to measure the protein expressions of Caspase-3 and GFAP. Compared with wild-type mice, VHL heterozygous mice showed less Caspase-3+ cells and more GFAP+ cells in ischemic boundary zone at 7 days after MCAO (Fig. 4A ).
Quantitative analysis revealed that VHL heterozygous mice exhibited a significantly lower number of Caspase-3+ and a higher number of GFAP GFAP+: 67.6 ± 13.1 cells/mm2) (P < 0.01, Fig. 4B ). We further performed Western blot analysis to explore whether VHL deletion could regulate portion expression of p-AKT and p-GSK-3β, two survival molecules associated with HIF-1α. We found that the protein expressions of p-AKT and p-GSK-3β in the ischemic boundary zone were significantly lower 7 days after MCAO, compared with the sham group. However, VHL heterozygous mice showed significantly higher p-AKT (P < 0.05) and p-GSK-3β (P < 0.01) levels compared to wild type mice ( Fig. 4C-E) . Collectively, these results indicated that VHL deletion can demonstrate neuroprotective effects by inhibition of HIF-1α and elevation of p-AKT and p-GSK-3β in the ischemic boundary zone.
| DISCUSSION
In this study, we generated VHL heterozygous knockout mice by TALENs, and demonstrated that VHL heterozygous mice did not show predisposition to the development of HBs and that a loss of one allele of the VHL gene did not induce new mutation of another alleles in CNS over the lifetime. Interestingly, we found that these VHL+/− mice exhibited smaller infarct volume by enhanced angiogenic ability, and
showed significantly improved neurological function in response to acute cerebral ischemia. To the best of our knowledge, this is the first study showing that the functional status via VHL heterozygous gene knockout is related to the growth of blood vessels in vivo under normal conditions and in severe brain ischemia. We also found that partly inactivation of the VHL function will offer a novel attacking approach for the therapy of acute cerebral ischemia.
The underlying mechanism linking VHL inactivation with the pathogenesis of CNS-HBs remains to be uncovered. In the present study, the offspring of VHL knockout mice carried VHL heterozygous or wild-type, with inheritance of all produced specific mutations of the VHL gene to the next generation. However, homozygous VHL−/− mice were not available in this study, consistent with previous reports that conferring to survive in a particular environment. [28] [29] [30] Our results also suggested a much bigger difference of between the two mutation rates in each allele of VHL gene within HBs, which could not be explained by random mutation, need to explore the underlying mechanism either other genetic affection or/and environmental insult. [31] [32] [33] All inherited VHL-defect carriers are in a sub-clinical status that requires effective management. 34, 35 These individuals with VHL Subsequently, we further detected enhanced expression of p-AKT and p-GSK-3β in heterozygous VHL mice after MCAO. p-AKT and p-GSK-3β protein expressions could be upregulated by EPO, 40, 41 and could provide neuroprotection, 42 both of them also are associated with reduced apoptosis in cortical neurons. 43 This was supported by our study that the number of Caspase-3+ neural cells was decreased in the ischemic boundary zone of heterozygous VHL mice after MCAO.
Moreover, the survival effect of VHL deletion was also confirmed in mice with spinal cord injury, in which VHL was co-localized with caspase-3 in neurons, and neuronal apoptosis was significantly reduced by VHL depletion through short interfering RNA. 44 We also found increased GFAP+ neural cells in heterozygous VHL mice. The enhanced GFAP+ cells were found to activate astrocytes, reduce neuronal death following brain ischemia, 45 and were associated with neuroprotective agent 2-oxoglutarate and Ilexonin A, 46, 47 indicating that neuronal regeneration might be enhanced in heterozygous VHL mice.
In conclusion, we demonstrated that mice with a loss of one allele of the VHL gene exhibited normal phenotypes without evidence of predisposition to the development of CNS-HBs. Heterozygous VHL +/− mice exhibited the neuroprotective response to acute cerebral ischemia/reperfusion injury due to enhanced angiogenesis by HIFdependent regulation and HIF-independent Twist 1 signaling.
Increased expressions of p-AKT and p-GSK-3β indicated reduced neuronal apoptosis, as evidenced by elevated Caspase-3+ and GFAP+ cells in the ischemic boundary zone. Our findings provide evidence of loss function of VHL as a precise therapeutic target in acute cerebral ischemia. Further investigations are needed to evaluate the efficacy and safety of heterozygous VHL knockout in the neuroprotection of cerebral ischemia based on the risk-to-benefit ratio.
